Search for a trial

A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study)

To assess the safety and efficacy of DBV712 in initiating desensitisation of peanut in children aged 1 to 3 years with peanut allergy, after 12 months of treatment with Epicutaneous Immunotherapy EPIT).

EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM
CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC
CHILDREN (EPOPEX)

This study has been transitioned to CTIS with ID 2024-515703-19-00 check the CTIS register for the current data. The objectives of this follow-up study of the EPITOPE study are:• To assess the clinical benefit of Viaskin Peanut after up to 3 years…